Delisting risk
Imunon (IMNN)
Developing localized DNA immunotherapy for advanced ovarian cancer.
$1.69
Pre-market+0.11 (+7.30%)
At close$1.58(−1.56%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions18 holders · as of Mar 31, 2026 | 11.98% | 503.6K shares | |
| Insiders10 holders · as of Sep 1, 2026 | 7.25% | 304.8K shares | |
| Otherremainder | 80.77% | 3.39M shares |
4.20M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.61M in the company's Sep 3, 2026 report, 4.20M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
18 holders · 503.6K shares · 3 new positions · 9 increased · 3 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 348.3K | 8.29% | +81.4K | May 15, 2026 |
| Vanguard Capital Management LLC | 48.1K | 1.14% | +48.1Knew | May 15, 2026 |
| Riverview Capital Advisers, LLC | 34.4K | 0.82% | 0 | May 14, 2026 |
| Geode Capital Management, LLC | 33.2K | 0.79% | +12.0K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 13.3K | 0.32% | +13.3Knew | May 8, 2026 |
| HRT Financial LP | 12.1K | 0.29% | +12.1Knew | May 14, 2026 |
| BlackRock, Inc. | 4.5K | 0.11% | 0 | May 13, 2026 |
| Wells Fargo & Company/MN | 3.3K | 0.08% | −96 | Jul 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 396.7K | 13G | May 15, 2026 ↗ |
| Opportunity Master Fund, SPC – Segregated Master Portfolio Bincl. Capital LLC, Khatri | 9.90% | 13G | Nov 14, 2024 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,525 | $1.56 | 2,896 |
| Aug 17, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,449 | $1.63 | 2,896 |
| Aug 3, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,541 | $1.57 | 2,896 |
| Jul 20, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,150 | $1.78 | 2,896 |
| Jul 6, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 920 | $1.88 | 2,896 |
| Jun 29, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 11,800 | $1.75 | 2,896 |
CongressHouse and Senate disclosures
Not reported.
